David L. Veenstra

David L. Veenstra

Auto-generated profile, based on publicly available information

David L. Veenstra

University of Washington, Seattle, WA, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 1999 in JAMA
Verified
Journal Article
Closed access
PDF file
DVDavid L. Veenstra
David L. Veenstra
SSSanjay Saint
Sanjay Saint
SSSomnath Saha
Somnath Saha
TLThomas Lumley
Thomas Lumley
SSSean D. Sullivan
Sean D. Sullivan
Review from JAMA — Efficacy of Antiseptic-Impregnated Central Venous Catheters in Preventing Catheter-Related Bloodstream Infection — A Meta-analysis — ContextCentral venous catheters impregnated with chlorhexidine and silver sulfadiazine have recently been introduced for the prevention of catheter-related infections. However, there remains some uncertainty regarding the efficacy of these catheters because of conflicting reports in the literature.ObjectiveTo evaluate the efficacy of chlorhexidine–silver sulfadiazine–impregnated central venous catheters in the prevention of catheter-related bloodstream infection.Data SourcesStudies identified from a computerized search of the MEDLINE database from January 1966 to January 1998, reference lists of identified articles, and queries of principal investigators and the catheter manufacturer.Study SelectionRandomized trials comparing chlorhexidine–silver sulfadiazine–impregnated central venous catheters with nonimpregnated catheters were included. The outcomes assessed were catheter colonization and catheter-related bloodstream infection confirmed by catheter culture.Data ExtractionTwelve studies met the inclusion criteria for catheter colonization and included a total of 2611 catheters. Eleven studies with a total of 2603 catheters met the inclusion criteria for catheter-related bloodstream infection. Most patients in these studies were from groups considered to be at high risk for catheter-related infections. Summary statistics were calculated using Mantel-Haenszel methods under a fixed-effects model.Data SynthesisThe summary odds ratio for catheter colonization was 0.44 (95% confidence interval [CI], 0.36-0.54; P<.001), indicating a significant decrease in catheter colonization associated with impregnated catheters. The studies examining the outcome of primary interest, catheter-related bloodstream infection, had a summary odds ratio of 0.56 (95% CI, 0.37-0.84; P=.005).ConclusionsCentral venous catheters impregnated with a combination of chlorhexidine and silver sulfadiazine appear to be effective in reducing the incidence of both catheter colonization and catheter-related bloodstream infection in patients at high risk for catheter-related infections.

11 August 1999 in JAMA
Verified
Journal Article
Open access
PDF file
DVDavid L. Veenstra
David L. Veenstra
SSSanjay Saint
Sanjay Saint
SSSean D. Sullivan
Sean D. Sullivan
Central venous catheters are essential in caring for many hospitalized patients who are critically ill and those requiring repeated venous access. Despite the advantages of their use, such as the ability to administer medications and large fluid volumes, central venous catheters are associated with mechanical and significant infectious complications.1 Catheter-related bloodstream infection (CR-BSI) occurs with 3% to 7% of catheters and affects more than 200,000 patients per year in the United States.2,3 The attributable mortality of CR-BSI ranges from approximately 10% to 25%, and CR-BSI has been associated with significant increases in the length of hospitalization and medical care costs.4-7

20 June 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CGCarlos J. Gallego
Carlos J. Gallego
BSBrian H. Shirts
Brian H. Shirts
CBCaroline S. Bennette
Caroline S. Bennette
GGGreg Guzauskas
Greg Guzauskas
LALaura M. Amendola
Laura M. Amendola
DVDavid L. Veenstra
David L. Veenstra
Purpose: To evaluate the cost effectiveness of next-generation sequencing (NGS) panels for the diagnosis of colorectal cancer and polyposis (CRCP) syndromes in patients referred to cancer genetics clinics.Patients and Methods: We developed a decision model to evaluate NGS panel testing compared with current standard of care in patients referred to a cancer genetics clinic. We obtained data on the prevalence of genetic variants from a large academic laboratory and calculated the costs and health benefits of identifying relatives with a pathogenic variant, in life-years and quality-adjusted life-years (QALYs). We classified the CRCP syndromes according to their type of inheritance and penetrance of colorectal cancer. One-way and probabilistic sensitivity analyses were conducted to assess uncertainty.Results: Evaluation with an NGS panel that included Lynch syndrome genes and other genes associated with highly penetrant CRCP syndromes led to an average increase of 0.151 year of life, 0.128 QALY, and $4,650 per patient, resulting in an incremental cost-effectiveness ratio of $36,500 per QALY compared with standard care and a 99% probability that this panel was cost effective at a threshold of $100,000 per QALY. When compared with this panel, the addition of genes with low colorectal cancer penetrance resulted in an incremental cost-effectiveness ratio of $77,300 per QALY.Conclusion: The use of an NGS panel that includes genes associated with highly penetrant CRCP syndromes in addition to Lynch syndrome genes as a first-line test is likely to provide meaningful clinical benefits in a cost-effective manner at a $100,000 per QALY threshold.

14 September 2000 in AAPS PharmSci
Verified
Journal Article
Closed access
PDF file
DVDavid L. Veenstra
David L. Veenstra
MHMitchell K. Higashi
Mitchell K. Higashi
KPKathryn A. Phillips
Kathryn A. Phillips

13 November 2014 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
CBCaroline S. Bennette
Caroline S. Bennette
CGCarlos J. Gallego
Carlos J. Gallego
WBWylie Burke
Wylie Burke
GJGail P. Jarvik
Gail P. Jarvik
DVDavid L. Veenstra
David L. Veenstra
Purpose: The American College of Medical Genetics and Genomics (ACMG) recommended that clinical laboratories performing next-generation sequencing analyze and return pathogenic variants for 56 specific genes it considered medically actionable. Our objective was to evaluate the clinical and economic impact of returning these results. Methods: We developed a decision-analytic policy model to project the quality-adjusted life-years and lifetime costs associated with returning ACMG-recommended incidental findings in three hypothetical cohorts of 10,000 patients. Results: Returning incidental findings to cardiomyopathy patients, colorectal cancer patients, or healthy individuals would increase costs by $896,000, $2.9 million, and $3.9 million, respectively, and would increase quality-adjusted life-years by 20, 25.4, and 67 years, respectively, for incremental cost-effectiveness ratios of $44,800, $115,020, and $58,600, respectively. In probabilistic analyses, returning incidental findings cost less than $100,000/quality-adjusted life-year gained in 85, 28, and 91%, respectively, of simulations. Assuming next-generation sequencing costs $500, the incremental cost-effectiveness ratio for primary screening of healthy individuals was $133,400 (<$100,000/quality-adjusted life-year gained in 10% of simulations). Results were sensitive to the cohort age and assumptions about gene penetrance. Conclusion: Returning incidental findings is likely cost-effective for certain patient populations. Screening of generally healthy individuals is likely not cost-effective based on current data, unless next-generation sequencing costs less than $500. Genet Med 17 7, 587–595.

1 November 2010 in PharmacoEconomics
Verified
Journal Article
Closed access
PDF file
WWWilliam B. Wong
William B. Wong
JCJosh J. Carlson
Josh J. Carlson
RTRahber Thariani
Rahber Thariani
DVDavid L. Veenstra
David L. Veenstra